Homeostasis between indigenous intestinal flora and host response may be broken in inflammatory bowel disease. The present study explores whether repeated oral administration of intestinal flora antigens can protect mice against dextran sodium sulphate (DSS)-induced colitis. Sonicates of Gram-positive, Gram-negative, or anaerobic resident bacteria isolated from mouse intestinal flora were fed to BALB/c mice by gastric gavage, with or without cholera toxin. After four weekly doses of 1 mg of these antigen preparations (or of PBS as control), DSS colitis was induced. One week later colitis was evaluated by clinical scores and histology. Mice fed a pool of the three sonicates had decreased inflammation scores (5 (1-14); median (range)) compared with PBS-fed control animals (15 (7-19); P < 0.05). Decreased inflammation was observed in mice fed anaerobic bacteria antigens (7 (6-11); P < 0.05 versus control), but not in mice fed a pool of Gram-positive and -negative sonicates (16 (12-16)). Inflammation scores of mice fed antigens with cholera toxin were similar to those of PBS-fed control animals. DSS-induced colitis can be suppressed by oral administration of normal intestinal flora antigens containing anaerobes.

Institute of Microbiology Academy of Sciences of the Czech Republic and Department of Internal Medicine Postgraduate Institute of Gastroenterology Central Military Hospital Prague Czech Republic

See more in PubMed

Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clinics North Am. 1995;24:475–507. PubMed

Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde K-H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995;102:448–55. PubMed PMC

Lee E. Split ileostomy in the treatment of Crohn’s disease of the colon. Ann R Coll Surg Eng. 1975;56:94–102. PubMed PMC

D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7. PubMed

Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328–32. PubMed

Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. NEJM. 1997;337:1029–35. PubMed

van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology. 1997;113:383–9. PubMed

Thayer WR, Coutu JA, Chiodini RJ, Van Kruiningen HJ, Merkal RS. Possible role of Mycobacteria in inflammatory bowel disease. Mycobacterial antibodies in Crohn’s disease. Dig Dis Sci. 1984;29:1080–5. PubMed

Kobayashi K, Brown WR, Brennan PJ, Blaser MJ. Serum antibodies to mycobacterial antigens in active Crohn’s disease. Gastroenterology. 1988;94:1404–11. PubMed

Brunello F, Pera A, Martini S, et al. Antibodies to Mycobacterium paratuberculosis in patients with Crohn’s disease. Dig Dis Sci. 1991;36:1741–5. PubMed

Rowbotham DS, Howdle PD, Trejdosiewicz LK. Peripheral cell mediated immune response to mycobacterial antigens in inflammatory bowel disease. Clin Exp Immunol. 1995;102:456–61. PubMed PMC

Targan SR, Murphy LK. Clarifying the causes of Crohn’s. Nat Med. 1995;1:1241–3. PubMed

Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde K-H, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996;26:934–8. PubMed

Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253–61. PubMed

Kühn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell. 1993;75:263–74. PubMed

Strober W, Ehrhardt RO. Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell. 1993;78:203–95. PubMed

Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human B2 microglobulin transgenic rats. J Clin Invest. 1996;98:945–53. PubMed PMC

Sartor RB. The role of endogenous luminal bacteria and bacterial products in the pathogenesis of experimental enterocolitis and systemic inflammation. In: Kagnoff MF, Kiyono H, editors. Essentials of mucosal immunology. New York: Academic Press; 1996. pp. 307–20.

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702. PubMed

Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344–67. PubMed

Cebra JJ, Jiang H-Q, Sterzl J, Tlaskalova-Hogenova H. The role of mucosal microbiota in the development and maintenance of the mucosal immune system. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, editors. Mucosal immunology. New York: Academic Press; 1998. pp. 267–80.

Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237–40. PubMed

Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol. 1996;157:2174–85. PubMed

Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996;183:2605–16. PubMed PMC

Pierre P, Denis O, Bazin H, Mbongolo Mbella E, Vaerman JP. Modulation of oral tolerance to ovalbumin by cholera toxin and its B subunit. Eur J Immunol. 1992;22:3179–82. PubMed

Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol. 1984;133:2892–7. PubMed

Lycke N. The mechanisms of cholera toxin adjuvanticity. Res Immunol. 1997;148:504–20. PubMed

Hornquist E, Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol. 1993;23:2136–43. PubMed

Michetti P, Porta N, Mahan MJ, Slauch JM, Mekelalanos JJ, Blum AL, Kraehenbuhl JP, Neutra MR. Monoclonal immunoglobulin A prevents adherence and invasion of polarized epithelial cell monolayers by Salmonella typhimurium. Gastroenterology. 1994;107:915–23. PubMed

Madsen KL, Foyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999;116:1107–14. PubMed

Lycke N, Karlsson U, Sjolander A, Magnusson KE. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol. 1991;33:691–8. PubMed

Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sodium sulphate-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994;107:1643–52. PubMed

Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res. 1996;45:181–91. PubMed

Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238–49. PubMed

Rath HC, Schultz M, Dieleman LA, Li F, Kolbl H, Falk W, Scholmerich J, Sartor RB. Selective vs. broad spectrum antibiotics in the prevention and treatment of experimental colitis in two rodent models. Gastroenterology. 1998;114:A1067.

Gorbach SL, Nahas L, Lerner PI, Weinstein L. Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology. 1967;53:845–55. PubMed

Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun. 1995;63:3904–13. PubMed PMC

Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992;176:1355–64. PubMed PMC

Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA. 1994;91:6688–92. PubMed PMC

Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997;18:335–43. PubMed

In Vitro Characterization of Gut Microbiota-Derived Commensal Strains: Selection of Parabacteroides distasonis Strains Alleviating TNBS-Induced Colitis in Mice

The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases

Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition

Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice

The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice